榄香烯联合奈达铂治疗恶性胸腹水临床观察  

Clinical observation of elemene combined with nedaplatin in the treatment of malignant pleural effusion

作　　者：王帅[1] 刘素艳[1] 李艳艳[1] 毛晓江 常娜[2] 付文娟[2] 佟玲[1] WANG Shuai;LIU Su yan;LI Yan-yan;MAO Xiao-jiang;CHANG Na;FU Wen-juan;TONG Ling(Hebei Tangshan People＇s Hospital,Tangshan 063000,P.R.China;Hebei Tangshan Food and Drug Inspection Center,Tangshan 063000,P.R.China)

机构地区：[1]唐山市人民医院药剂科,河北唐山063000 [2]唐山市人民医院肿瘤内科放化五,河北唐山063000 [3]唐山市食品药品检验中心,河北唐山063000

出　　处：《中华肿瘤防治杂志》2018年第18期1328-1331,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的恶性胸腹水是肿瘤晚期出现的临床并发症，其压迫胸腹部脏器产生胸闷、呼吸困难和疼痛等症状，影响患者的生活质量。本研究以胸腹腔灌注药物的方式，进行榄香烯联合奈达铂对恶性胸腹水的疗效比较。方法选取2015-09—01—2016-09—30唐山市人民医院治疗的96例恶性胸腹水患者，根据治疗方法分为对照组48例和观察组48例，对照组单纯给予奈达铂治疗，观察组给予榄香烯联合奈达铂治疗，观察两组患者治疗后的疗效、免疫功能及不良反应状况，分析榄香烯联合奈达铂治疗恶性胸腹水的临床效果。结果治疗后观察组胸腹水缓解率为81．25％，优于对照组的62．5％，差异有统计学意义，P=0．04。治疗前后两组患者CD4以及CD4／CD8明显升高（P〈0．001），CD8差异无统计学意义，P=0．769。治疗后两组惠者均有发热、胸痛、胃肠道反应、血白细胞计数下降等药物不良反应，发热（P=0．69）、胸痛（P=0．24）及胃肠道反应（P=0．63）不良反应的发生率差异均无统计学意义。血白细胞下降不良反应中，对照组出现的人数比观察组明显偏高，差异有统计学意义，P〈0．05。结论榄香烯联合奈达铂治疗恶性胸腹水能够有效提高治疗效果，提高患者免疫力并减少不良反应的发生，值得临床推广使用。OBJECTIVE Malignant pleural effusion,a clinical complication emerged in the advanced stage of neopla sia,inserts pressure against abdominal organs, causing symptoms like chest distress, breathing difficulties and pain and af fecting quality of life for the patients. This study compared the clinical efficacy of combining elemene with nedaplatin in treating malignant pleural effusion by intracavitary perfusion. METHODS Totally 96 patients treated for malignant pleural effusion in Tangshan People＇ s Hospital from 1 September 2015 to 30 September 2016 were selected, in which the 48 cases treated with nedaplatin alone form a control group while the 48 cases treated with elemene together with nedapla tin form an observation group. The therapeutic effect,immune function and adverse reactions of the two groups were ob served,leading to analysis on the clinical efficacy of elemene combined with nedaplatin in the treatment of malignant pleural effusion. RESULTS After the treatment,the remission rate of pleural effusion was 81. 25% in the observation group, higher than the 62.5 % seen in the control group, with statistically significant difference（P = 0.04）. Before and after the treatment,CD4 and CD4/CD8 in both groups of patients have significantly increased（P〈0. 001） while the difference in CD8 had shown no statisticaL significance（P= 0. 769）. After the treatment, both groups have patients experiencing adverse reactions like fever, chest pain, gastrointestinal reactions, and drop in blood leukocyte counts, while the probabilities of their occurrences：fever（P=0.69）,chest pain（P=0.24） and gastrointestinal reactions（P=0.63） had shown no statistically significant differences in the two groups. For the adverse reaction of blood leukocyte counts decrease,its number of occurrences in the control group was sharply higher than that in the observation group, showing have statistically signifi cant difference（P〈0.05）. CONCLUSIONS Elemene combined with nedaplatin can effectively improve the eff

关 键 词：恶性胸腹水 榄香烯 奈达铂 疗效 

分 类 号：R73[医药卫生—肿瘤]